Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Cap­i­tal talks a lot about con­ti­nu­ity.

Rafaèle Tord­j­man had spot­light­ed that con­cept ever since she start­ed build­ing the firm in 2018, promis­ing to go the ex­tra mile(s) with biotech en­tre­pre­neurs while push­ing them to reach pa­tients faster.

Co­in­ci­den­tal­ly, the lack of con­ti­nu­ity was one of the sore spots list­ed in a re­port about the Eu­ro­pean health­care sec­tor pub­lished that same year by the Eu­ro­pean In­vest­ment Bank — whose fund is one of the LPs, along­side the Amer­i­can pen­sion fund Teacher Re­tire­ment Sys­tem of Texas and Sin­ga­pore’s Temasek, to help Jeito close its first fund at $630 mil­lion (€534 mil­lion). As pre­vi­ous­ly re­port­ed, Sanofi had chimed in €50 mil­lion, mark­ing its first in­vest­ment in a French life sci­ences fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.